

HIGHLY ACTIVE ANTIRETROVIRAL THERAPY PRESCRIPTIONS IN NAIVE PATIENTS: IMPROVEMENT PLAN

A. Rodríguez-Perez¹, M.I. Sierra-Torres¹, M.D. Toscano-Guzmán¹, A. Monzón-Moreno¹, M. Soriano-Martinez¹, A. Lluch-Colomer¹, M.D. Santos-Rubio¹
IUGC Farmacia. Hospital Universitario Virgen del Rocío. Seville. Spain

TAR DE INICIO		
2 ITIAN + 1ITINN ó 1IP/r ó 1InInt		
Los 2 ITIAN recomendados son TDF/FTC y ABC/3TC		

TDF/FTC (245/200 mg) TRUVADA			
3er Fármaco	Nombres comerciales		Tomas
ITINN	EFV (600 mg)	ATRIPLA	QD
	RPV (25mg)	EVIPLERA	QD
	NVP (400 mg). 200mg 1 ^s 2 sem.	TRUVADA + NEVIRAPINA	QD
IP/r	DRV/r (800 mg)	TRUVADA + PREZISTA + NORVIR	QD
	ATV 300/r QD	TRUVADA + ATAZANAVIR + NORVIR	QD
	LPV/r	TRUVADA + KALETRA	BID/QD
InInt	RAL	TRUVADA + ISENTRESS	BID

ABC/3TC (600/300mg) KIVEXA			
3er Fármaco	Nombres comerciales		Tomas
ITINN	EFV	KIVEXA + SUSTIVA	QD
IP/r	ATV 300 /r	KIVEXA + ATAZANAVIR + NORVIR	QD
	LPV/r	KIVEXA + KALETRA	BID/QD
InInt	RAL	KIVEXA + ISENTRESS	BID

NO RECOMENDADAS		
KIVEXA + EDURANT		
KIVEXA + PREZISTA		


Table with the allowed and not allowed antirretroviral combinations

WHAT WAS DONE?

An easy-to-read handout that summarized the main recommendations of GESIDA for the treatment of naive patients, treated with highly active antiretroviral therapy(HAART).

MADE BY A MULTIDISCIPLINARY GROUP OF CLINICAL PHARMACISTS AND PHYSICIANS


DISSEMINATED THROUGH CLINICAL SESSIONS



WHY WAS IT DONE?

According to the guidelines and recommendations for the rational use of medication, prescriptions of HAARTs must be standardized following the principles of efficiency and based on the best evidence available.

WHAT HAS BEEN ACHIEVED?



HOW WAS IT DONE?

We did not have any problem implementing these recommendations or organizing the clinical sessions

WHAT NEXT?

The multidisciplinary team has periodic meetings to evaluate the adherence to the recommendations and to study news reported by GESIDA. The economic impact of the practice is planned to be evaluated